Physostigmine - Allergan

Drug Profile

Physostigmine - Allergan

Alternative Names: Nicosim; Synapton

Latest Information Update: 02 Sep 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Forest Laboratories
  • Developer Forest Laboratories; Neurobiological Technologies
  • Class Alkaloids; Antidementias; Antidotes; Antiglaucomas; Phenylcarbamates; Small molecules; Smoking cessation therapies
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease; Smoking withdrawal

Most Recent Events

  • 04 Sep 2001 Discontinued-II for Alzheimer's disease in Germany (Transdermal)
  • 04 Sep 2001 No-Development-Reported for Alzheimer's disease in Ireland (PO)
  • 04 Sep 2001 No-Development-Reported for Alzheimer's disease in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top